The aim of this film is to demonstrate that salvage radical prostatectomy can be performed preserving urinary continence and with a morbility rate comparable to that of radical prostatectomy performed de novo in patients with a previously untreated tumor. Three consecutive rises in PSA level, above the nadir PSA, and the presence of biopsy-proven prostate cancer, show a recurrent or persistent disease in a patient with prostate cancer, treated with full-dose radiation therapy. Thus, when patients present a life expectancy of at least 10 years and organ-confined disease, salvage radical prostatectomy is the only option of therapy most likely to achieve lasting local control.
MeetlinC.. The American Cancer Society National Prostate Cancer Detection Project and national patterns of prostate cancer detection and treatment.CA Cancer J Clin1997; 47: 265–72.
2.
LeeW.R., HanlonA.L., HanksG.E.. Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: the relationship between nadir level and disease-free survival.J Urol1996; 156: 450–3.
KubanD.A., El-MadhiA.M., SchellhammerP.. The significance of post-irradiation prostate biopsy with long-term follow-up.Int J Radiation Oncol Biol Phys1992; 24: 409–14.
5.
GheilerE.L., TefilliM.V., TiguertR.. Predictors for maximal outcome in patients undergoing salvage surgery for radiorecurrent prostate cancer.Urology1998, 51: 789.
6.
VaidyaA., and SolowayM.S.. Salvage radical prostatectomy for radiorecurrent prostate cancer: morbidity revisited.J Urol2000; 164: 1998–2001.
